Compounding in Dermatology Update – Part 2
In part 1 of this 2-part series, Dr. Kircik along with JDD authors Vlatka Agnetta MD, Abel Torres MD JD MBA, Seemal R. Desai MD, and Adelaide A. Hebert MD, reviewed the regulatory landscape of compounding in dermatology, including federal and state regulations. In part 2, they discuss FDA and USP Compounding Lists/ Categories and provide their final thoughts on in-office compounding.
FDA Compound …
In part 1 of this 2-part series, Dr. Kircik along with JDD authors Vlatka Agnetta MD, Abel Torres MD JD MBA, Seemal R. Desai MD, and Adelaide A. Hebert MD, reviewed the regulatory landscape of compounding in dermatology, including federal and state regulations. In part 2, they discuss FDA and USP Compounding Lists/ Categories and provide their final thoughts on in-office compounding.
FDA Compound … Continue reading "Compounding in Dermatology Update – Part 2"
Medication compounding is defined as any alteration, mixing, or combining of two or more ingredients that make the drug more specific to the needs of the patient.1 Compounded medications are used widely in patient care to meet their individual medical needs and maximize treatment outcomes. The Food and Drug Administration (FDA) and the United States Pharmacopeia (USP) have been the leading organiz … 
Morphea profunda. To the dermatologist, these words conjure images of hyperpigmented to violaceous, indurated, bound down atrophic plaques. We describe these lesions in our specialty’s vernacular, so that those we are conversing with can often surmise the diagnosis before even seeing the affected patient. But to the patient, it is the language of the diagnosis itself that has the most meaning. M … 
These are the issue highlights from the March issue of the JDD!
Azelaic acid 15% foam may be an efficacious therapy for rosacea while also offering a better side effect profile in Rosacea Treatment Satisfaction: Matching Adjusted Indirect Treatment Comparison Analysis of Metronidazole Gel or Cream vs Azelaic Acid Foam.
Nail Surgery Myths and Truths dispels common myths encount … 
Lichen myxedematosus (LM) is an idiopathic cutaneous mucinosis, commonly described as localized scleromyxedema. In contrast to scleromyxedema, there is typically no systemic involvement. Treatment options are limited and spontaneous resolution has been reported.
JDD authors Amaris Geisler BS, Mojgan Hosseinipour DO, Nikki S. Vyas MD, Robert Phelps MD, Charles Gropper MD, and Cindy Hoffman DO p … 